(Q33393356)

26 July 2017

title

Long term efficacy and safety of allopurinol and azathioprine or 6-mercaptopurine in patients with inflammatory bowel disease (English)

1 reference

inflammatory bowel diseases

26 July 2017

main subject

0 references

0 references

0 references

1 reference

1 reference

Yvette Leung

1

1 reference

26 July 2017

Miles P Sparrow

series ordinal

2

1 reference

26 July 2017

Marc Schwartz

series ordinal

3

1 reference

26 July 2017

Stephen B Hanauer

series ordinal

4

1 reference

26 July 2017

publication date

17 March 2009

1 reference

Journal of Crohn's and Colitis

26 July 2017

published in

1 reference

26 July 2017

volume

3

1 reference

26 July 2017

issue

3

1 reference

26 July 2017

page(s)

162-167

1 reference

A controlled double blind study of azathioprine in the management of Crohn's disease

26 July 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FJ.CROHNS.2009.02.003

Early combined immunosuppression or conventional management in patients with newly diagnosed Crohn's disease: an open randomised trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.CROHNS.2009.02.003

Randomised controlled trial of azathioprine and 5-aminosalicylic acid for treatment of steroid dependent ulcerative colitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.CROHNS.2009.02.003

Thiopurines in current medical practice: molecular mechanisms and contributions to therapy-related cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.CROHNS.2009.02.003

The clinical pharmacology of 6-mercaptopurine

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.CROHNS.2009.02.003

CD28-dependent Rac1 activation is the molecular target of azathioprine in primary human CD4+ T lymphocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.CROHNS.2009.02.003

Selective inhibition of inflammatory gene expression in activated T lymphocytes: a mechanism of immune suppression by thiopurines

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.CROHNS.2009.02.003

6-MP metabolite profiles provide a biochemical explanation for 6-MP resistance in patients with inflammatory bowel disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.CROHNS.2009.02.003

Allopurinol safely and effectively optimizes tioguanine metabolites in inflammatory bowel disease patients not responding to azathioprine and mercaptopurine

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.CROHNS.2009.02.003

Effect of allopurinol on clinical outcomes in inflammatory bowel disease nonresponders to azathioprine or 6-mercaptopurine

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.CROHNS.2009.02.003

Use of allopurinol with low-dose 6-mercaptopurine in inflammatory bowel disease to achieve optimal active metabolite levels: a review of four cases and the literature

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.CROHNS.2009.02.003

Long-term outcome of using allopurinol co-therapy as a strategy for overcoming thiopurine hepatotoxicity in treating inflammatory bowel disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.CROHNS.2009.02.003

Initial clinical experience with allopurinol-thiopurine combination therapy in pediatric inflammatory bowel disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.CROHNS.2009.02.003

Veno-occlusive disease (VOD) in Crohn's disease (CD) treated with azathioprine

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.CROHNS.2009.02.003

Nodular regenerative hyperplasia in patients with inflammatory bowel disease treated with azathioprine

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.CROHNS.2009.02.003

A simple index of Crohn's-disease activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.CROHNS.2009.02.003

6-Mercaptopurine metabolism in Crohn's disease: correlation with efficacy and toxicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.CROHNS.2009.02.003

Pharmacogenomics and metabolite measurement for 6-mercaptopurine therapy in inflammatory bowel disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.CROHNS.2009.02.003

6-tioguanine monitoring in steroid-dependent patients with inflammatory bowel diseases receiving azathioprine.

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.CROHNS.2009.02.003

Association of 6-thioguanine nucleotide levels and inflammatory bowel disease activity: a meta-analysis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.CROHNS.2009.02.003

Low-dose allopurinol plus azathioprine/cyclosporin/prednisolone, a novel immunosuppressive regimen

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.CROHNS.2009.02.003

The role of xanthine oxidase in thiopurine metabolism: a case report

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.CROHNS.2009.02.003

Influence of xanthine oxidase on thiopurine metabolism in Crohn's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.CROHNS.2009.02.003

Observations on the use of allopurinol in combination with azathioprine or mercaptopurine

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.CROHNS.2009.02.003

Allopurinol in addition to 5-aminosalicylic acid based drugs for the maintenance treatment of ulcerative colitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.CROHNS.2009.02.003

Allopurinol as prophylaxis against pouchitis following ileal pouch-anal anastomosis for ulcerative colitis. A randomized placebo-controlled double-blind study

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.CROHNS.2009.02.003

Prospective evaluation of the pharmacogenetics of azathioprine in the treatment of inflammatory bowel disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.CROHNS.2009.02.003

10.1016/J.CROHNS.2009.02.003

21 January 2018

Identifiers

DOI

1 reference

26 July 2017

1 reference